FDA Requires Labels on GLP-1 Drugs to Warn of Sudden Vision Loss @kitv
FDA Requires Labels on GLP-1 Drugs to Warn of Sudden Vision Loss  @kitv
Uploaded November 2026 | Updated November 2026, 1 day ago
The FDA is requiring updated safety warnings on popular GLP-1 weight-loss and diabetes drugs—including Ozempic, Wegovy, Mounjaro, and Zepbound—over a potential increased risk of sudden vision loss. The rare eye condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), is caused by decreased blood flow to the front of the optic nerve. The regulatory agency's decision to mandate the label changes follows a thorough review of clinical trial data, case reports, and post-market procedures. While drug manufacturers say they are evaluating the update and remain confident in their medications' overall benefit-risk profiles, health officials advise patients not to stop taking their prescriptions without consulting a doctor. However, patients are urged to be aware of the potential risk and to contact a healthcare professional immediately if they notice any sudden vision changes, such as blurred vision or blind spots.
FDA Requires Labels on GLP-1 Drugs to Warn of Sudden Vision LossYMCA provides free holiday food boxes to Palolo Homes familiesTrusted Local Vets Caring for Your PetsHalawa Correctional Facility inmate indicted for allegedly beating fellow inmate to deathAAA Projects 81 Million Thanksgiving Travelers, A Slight Drop From Last YearHonolulu Chinatown bar Manifest closing after 16 yearsHauʻoli Lā Hānau on this November 21, 2025Smile Again with Confidence!Watch Moana 2 in ʻŌlelo HawaiʻiOahu may finally get a legal race track after 20 yearsThats Not the Cost of War: Grieving Husband Demands Answers for Kuwait Drone StrikeDarth Vader’s Lightsaber Sells for $4.87 Million
Island News |

FDA Requires Labels on GLP-1 Drugs to Warn of Sudden Vision Loss

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER